HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Shanghai Junshi Bioscience - Here Are the Challenges

Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma

Industry Report - Insights on Hair Loss Prevention and Hair Growth Industry

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<p>On June 25, 2021, “something strange” happened to <a href="https://www.smartkarma.com/entities/3sbio-inc" target="_blank" data-smartkarma-citation="entities:459:1" rel="noopener">3SBio Inc (1530 HK)</a>. Its share price fell 16.61% in one day, closing at HK$10.14/share, and the market value decreased about HK$5 billion. On Monday, June 28, 2021, its share price continued to decline to HK$9.79/share. No matter which institutions reduced holdings, in fact, 3SBio's future performance still depends on the Company's fundamentals and business outlook. So, this insight mainly analyzed the important products, the pipeline and the concerns of 3SBio.</p>

On June 25, 2021, “something strange” happened to 3SBio Inc (1530 HK). Its share price fell 16.61% in one day, closing at HK$10.14/share, and the market value decreased about HK$5 billion. On Monday, June 28, 2021, its share price continued to decline to HK$9.79/share. No matter which institutions reduced holdings, in fact, 3SBio's future performance still depends on the Company's fundamentals and business outlook. So, this insight mainly analyzed the important products, the pipeline and the concerns of 3SBio.

Zhejiang Hisun Pharmaceutical Co, Ltd. (600267 CH)

3SBio Inc (1530.HK) - The Concerns and the Outlook